Methods  Background -Cysteinyl leukotriene release in association with airway inflam-Healthy non-smoking (for at least one year, no more than five pack years) male and female mation is a feature of clinical asthma. The acute effects of montelukast (MK-0476), asthmatic patients aged 18-54 years participated in the study. Patients were required a potent, orally administered, specific cysteinyl leukotriene receptor ant-to have a forced expiratory volume in one second (FEV 1 ) between 50% and 80% of preagonist, on airways obstruction was assessed in patients with mild to moderately dicted values, with at least a 15% increase in FEV 1 within 30 minutes of inhaling salbutamol severe asthma. Methods -Twenty two asthmatic subjects (180 g) at the prestudy visit.
was the mean of the measurements obtained imum percentage change in FEV 1 from baseline * Mean of two prestudy values.
-was performed at a significance level of p= 0.05. Formal testing within each subgroup of those using and not using inhaled corticosteroids was not performed as the study was were measured before each salbutamol dose and every 20 minutes for one hour after the not specifically designed to test this hypothesis.
With a sample size of 24 the study was last dose.
Patients in whom the FEV 1 fell by more than designed to have 80% power (p=0.025, two sided test) to detect a 0.25 litre (or 8.1%) 25% of the predose value or when clinically indicated were given inhaled salbutamol.
difference in the mean FEV 1 values between treatments.
  Montelukast (50 mg) and placebo capsules of Results Twenty men and two women with chronic identical appearance were supplied by Merck Research Laboratories, Rahway, NJ, USA. asthma entered and completed the study, 10 of whom used concomitant inhaled corticoPatients received five capsules of the appropriate combination of active or placebo steroids (table 1). The mean predose baseline FEV 1 values were comparable for each treatstudy medication at each administration. ment period and treatment group, as well as between patients with and without concomitant inhaled corticosteroids (data not shown).   For the prestudy and predosing values (each Neither period nor carryover effect was noted. In addition, no significant interaction treatment period) sets of at least three spirometric measurements were obtained on a was noted between users and non-users of inhaled corticosteroids. This observation sugpneumotachograph (Medical Graphics Corporation, CPF-S, St Paul, Minnesota, USA). At gests that the treatment effect was qualitatively similar in these groups. Since no interaction each time point after initial dosing at least two acceptable manoeuvres were performed. was observed, data from all patients were combined for analysis. During placebo treatment Patients were coached to achieve American Thoracic Society acceptability and re-three patients required salbutamol rescue and in the 100 mg treatment period two patients producibility criteria; the highest FEV 1 from each set of manoeuvres was selected for ana-were rescued after the spirometric measurements at hour 5. No patient required rescue lysis.
treatment during the 250 mg treatment period.
 
The ability of montelukast to cause broncho- The FEV 1 for all patients is shown in fig 1 as dilation was assessed by a pre-specified primary comparison of the mean maximum percentage a percentage change from the predose baseline value for each study period. Figure 2 sumchange in FEV 1 from the predose baseline value. As an additional assessment, the per-marises the results in patients receiving concomitant inhaled corticosteroids. For all centage change in FEV 1 from baseline at two, three, four, and six hours after administration patients there was a significant difference (p<0.05) between both active treatment groups and the differences in the change between active treatments and placebo were determined and placebo in the mean (SD) maximum percentage change in FEV 1 from predose baseline with corresponding 95% confidence intervals. Analysis of hours 6-9 was not pre-specified with values of 17.7 (13.6)%, 26.2 (17.3)%, and 26.1 (15.5)% for placebo, 100 mg and and not performed. The predose baseline FEV 1 subjects with baseline airflow limitation. Trials with other cysteinyl leukotriene receptor antagonists have demonstrated bronchodilation after both oral and intravenous administration. 250 mg montelukast treatments, respectively. The percentage point difference from placebo For example, single intravenous doses of MK-571 3 and MK-0679 4 caused bronchodilation in was 8.6% (95% CI 3.6 to 13.6) and 8.5% (95% CI 3.5 to 13.5) for the 100 mg and chronic asthmatics (approximately 15% change in FEV 1 from baseline value compared with 250 mg doses, respectively. Table 2 lists the differences between each active treatment placebo), and oral administration of 40 mg zafirlukast (ICI 204 219) resulted in a change group and 95% CI individually for hours 2-6. Addition of the second dose did not result in FEV 1 of approximately 6% from the baseline value compared with placebo. 5 in added benefit over the initial six hours of observation (fig 1) . In this study oral doses of montelukast (100 mg and 250 mg) caused comparable bronchodilation. Well controlled, sufficiently powered studies using lower doses of monte-  Following the administration of salbutamol be-lukast will be needed to investigate further the relationship between dose or plasma conginning at hour 9, the mean maximum percentage increase in FEV 1 from the predose centration and degree of bronchodilation.
This study was not specifically designed to baseline value was greater for both montelukast treatment groups compared with placebo, al-compare the treatment effect in patients using and not using inhaled corticosteroids. Howthough the differences were not statistically significant. Additionally, the magnitude of re-ever, it was found that montelukast caused 
